Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07).
- Author:
Hyejung CHA
1
;
Hee Chul PARK
;
Jeong Il YU
;
Tae Hyun KIM
;
Taek Keun NAM
;
Sang Min YOON
;
Won Sup YOON
;
Jun Won KIM
;
Mi Sook KIM
;
Hong Seok JANG
;
Youngmin CHOI
;
Jin Hee KIM
;
Chul Seung KAY
;
Inkyung JUNG
;
Jinsil SEONG
Author Information
- Publication Type:Practice Guideline ; Original Article
- Keywords: Hepatocellular carcinoma; Radiotherapy; Clinical practice pattern
- MeSH: Carcinoma, Hepatocellular*; Follow-Up Studies; Humans; Liver Neoplasms; Practice Patterns, Physicians'*; Radiation Oncology*; Radiotherapy*
- From:Cancer Research and Treatment 2017;49(1):61-69
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The aim of this study was to examine patterns of radiotherapy (RT) in Korean patients with hepatocellular carcinoma (HCC) according to the evolving guideline for HCC established by the Korean Liver Cancer Study Group-National Cancer Center (KLCSG-NCC). MATERIALS AND METHODS: We reviewed 765 patients with HCC who were treated with RT between January 2011 and December 2012 in 12 institutions. RESULTS: The median follow-up period was 13.3 months (range, 0.2 to 51.7 months). Compared with previous data between 2004 and 2005, the use of RT as a first treatment has increased (9.0% vs. 40.8%). Increased application of intensity-modulated RT resulted in an increase in radiation dose (fractional dose, 1.8 Gy vs. 2.5 Gy; biologically effective dose, 53.1 Gy10 vs. 56.3 Gy10). Median overall survival was 16.2 months, which is longer than that reported in previous data (12 months). In subgroup analysis, treatments were significantly different according to stage (p < 0.001). Stereotactic body RT was used in patients with early HCC, and most patients with advanced stage were treated with three-dimensional conformal RT. CONCLUSION: Based on the evolving KLCSG-NCC practice guideline for HCC, clinical practice patterns of RT have changed. Although RT is still used mainly in advanced HCC, the number of patients with good performance status who were treated with RT as a first treatment has increased. This change in practice patterns could result in improvement in overall survival.
